This paper reviews two innovated formulations namely Carbidopa-levodopa extended release formulation (Rytary) and Carbidopa-levodopa intestinal gel (Duodopa); with their respective clinical relevance in comparison to conventional pharmacological therapies. The expose also reviews a newly approved drug Pimavanserin (Nuplazid) formulated to address the issue of psychosis experienced by many suffers of Parkinson's disease in the late phase.